Skip to main content
. 2019 Mar 20;10(5):560–566. doi: 10.3892/mco.2019.1830

Figure 4.

Figure 4.

OS among the patients with EGFR or ALK mutations according to treatment modality. OS, overall survival; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; SRS, safety of stereotactic radiosurgery; WBRT, whole brain radiotherapy; CI, confidence interval.